CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 369 enrolled
Drug / intervention
Whole-body FDG PET-CT aloneother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02751710
NCT02751710N/ACompleted
CompareCT.gov

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

Ontario Clinical Oncology Group (OCOG)·interventional·Posted Apr 26, 2016·Updated Jan 19, 2024

In Brief

A clinical study evaluating Whole-body FDG PET-CT alone for Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4) and Stage IIb Breast Cancer (T3N0). Completed, enrolled 369 participants across 6 sites.

Detailed Summary

This trial is being conducted to determine the impact of whole body FDG PET-CT vs. conventional staging in the management of patients presenting with clinical Stage III breast cancer. Eligible consenting patients with ductal or mixed histology breast cancer will be randomized 1:1 to whole body FDG PET-CT or conventional staging. Eligible consenting patients with lobular only histology will be entered into a separate single arm prospective study and will undergo whole body FDG PET-CT, CT with contrast of the chest/abdomen \& pelvis and a bone scan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4), Stage IIb Breast Cancer (T3N0)
CountriesCanada
CollaboratorsCancer Care Ontario

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedApr 26, 2016
Enrollment StartDec 6, 2016
Primary CompletionMar 31, 2023
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 10.2 years ago

Interventions

Whole-body FDG PET-CT aloneother

FDG PET-CT imaging